The Europe amniotic products market is expected to grow from US$ 362.61 million in 2022 to US$ 582.01 million by 2028; it is estimated to grow at a CAGR of 8.2% from 2022 to 2028.
Demand for wound care biologics, such as amniotic membranes, has increased significantly due to the high prevalence of burn wounds. In 2019, a total of 8,378,122 new burns cases were recorded (95% UI, 10,363,109-6,531,887 cases). Burn fatality rates have been declining in many high-income nations, but child burn deaths are now ~7 times greater in low- and middle-income countries than in high-income countries. From 1990 to 2019, the burden of burns declined progressively and was thought to be reduced in most regions. Moreover, according to the Children's Burn Trust and the British Burn Association, 625 children are admitted to an NHS Burns Service each month due to burn or scald injuries. In 2017, the NHS's burns and scalds services treated more than 15,000 patients with these injuries, with a total cost of more than US$ 24.94 million (i.e., GBP 20 million). Also, out of these patients, more than 40 cases were extremely serious, with treatment procedures costing more than US$ 118,455.50 (GBP 95,000) per person. Biologic materials are now used in various surgical procedures due to recent tissue harvesting, screening, and banking advancements. Burns, nerve regeneration, soft tissue reconstructive surgeries, ophthalmic surgeries, and diabetic foot ulcer surgeries are among the applications for amniotic membranes. Amniotic membrane has been demonstrated to improve healing rates, reduce infection rates, shorten hospital stays, and reduce the number of dressing changes required in burn patients. Therefore, it has a lot of scopes to improve outcomes and save money. The amniotic membrane is helpful in treating chronic wounds, such as diabetic foot ulcers. It also holds tremendous potential for the treatment of donor skin graft sites, wounds treated with skin grafts, and partial thickness burns. Thus, increasing burn cases are driving the amniotic product market in Europe.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe amniotic products market . The Europe amniotic products market is expected to grow at a good CAGR during the forecast period.
Demand for wound care biologics, such as amniotic membranes, has increased significantly due to the high prevalence of burn wounds. In 2019, a total of 8,378,122 new burns cases were recorded (95% UI, 10,363,109-6,531,887 cases). Burn fatality rates have been declining in many high-income nations, but child burn deaths are now ~7 times greater in low- and middle-income countries than in high-income countries. From 1990 to 2019, the burden of burns declined progressively and was thought to be reduced in most regions. Moreover, according to the Children's Burn Trust and the British Burn Association, 625 children are admitted to an NHS Burns Service each month due to burn or scald injuries. In 2017, the NHS's burns and scalds services treated more than 15,000 patients with these injuries, with a total cost of more than US$ 24.94 million (i.e., GBP 20 million). Also, out of these patients, more than 40 cases were extremely serious, with treatment procedures costing more than US$ 118,455.50 (GBP 95,000) per person. Biologic materials are now used in various surgical procedures due to recent tissue harvesting, screening, and banking advancements. Burns, nerve regeneration, soft tissue reconstructive surgeries, ophthalmic surgeries, and diabetic foot ulcer surgeries are among the applications for amniotic membranes. Amniotic membrane has been demonstrated to improve healing rates, reduce infection rates, shorten hospital stays, and reduce the number of dressing changes required in burn patients. Therefore, it has a lot of scopes to improve outcomes and save money. The amniotic membrane is helpful in treating chronic wounds, such as diabetic foot ulcers. It also holds tremendous potential for the treatment of donor skin graft sites, wounds treated with skin grafts, and partial thickness burns. Thus, increasing burn cases are driving the amniotic product market in Europe.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe amniotic products market . The Europe amniotic products market is expected to grow at a good CAGR during the forecast period.
Europe Amniotic Products Market Segmentation
The Europe amniotic products market is bifurcated based on type, application, end user and country.- Based on type, the market is segmented into amniotic membranes, and amniotic suspensions. The amniotic membranes segment dominated the market in 2022 and is expected to be fastest growing during forecast period.
- Based on application, the market is segmented into wound care, orthopedics, ophthalmology, and other applications. The wound care segment dominated the market in 2022 and orthopedics segment is expected to be fastest growing during forecast period.
- Based on end user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and other end users. The hospitals and clinics segment dominated the market in 2022 and ambulatory surgical centers segment is expected to be fastest growing during forecast period.
- Based on country, the Europe amniotic products market is segmented into the UK, Germany, France, Italy, Spain, and Rest of Europe.
Table of Contents
1. Introduction
3. Research Methodology
4. Europe Amniotic Products Market - Market Landscape
5. Amniotic Products Market- Key Market Dynamics
6. Amniotic Products Market- Europe Analysis
7. Europe Amniotic Products Market Revenue and Forecast to 2028 - by Type
8. Europe Amniotic Products Market Revenue and Forecast to 2028 - by Application
9. Europe Amniotic Products Market Revenue and Forecast to 2028 - by End User
10. Europe Amniotic Products Market Revenue and Forecast to 2028 - by Country
11. Europe Amniotic Products Market-Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Integra LifeSciences
- Katena Products. Inc.
- MiMedx
- NuVision Biotherapies Ltd
- Organogenesis, Inc.
- Sanuwave and Sanuwave Health, Inc.
- Smith & Nephew
- Stryker
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 132 |
| Published | September 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 362.61 Million |
| Forecasted Market Value ( USD | $ 582.01 Million |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Europe |
